Questionnaire

For people with T2DM and overweight/obesity, weight loss may exert benefits that extend beyond glycaemic management to improve cardiometabolic risk factors and quality of life.

The largest modifiable biomarker associated with gains in life-years for patients with T2DM is:

The benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with T2DM include:

Clinically meaningful changes in the pathophysiology of T2DM and the possibility of disease remission can occur with a body weight loss of:

The gut-derived factor that is responsible for the greatest augmentation of insulin release after nutrient ingestion is:

Documented effects of GIP in the adipose tissue include:

TZP plasma concentrations are significantly reduced in patients with T2DM and with renal or hepatic impairment.

Demonstrated therapeutic actions of TZP treatment in T2DM include:

There is an increased risk of hypoglycaemia when TZP is used in combination with:

 Although mostly mild or moderate in severity and occurring during dose escalation, the most common adverse event associated with TZP treatment is:

Compared with SEM 1mg as add-on to metformin in participants with T2DM and overweight/obesity, the SURPASS-2 trial demonstrated that participants using 5mg, 10mg or 15mg TZP plus metformin more rapidly achieved:

Compared with SEM-treated participants in SURPASS-2, TZP-treated participants demonstrated significantly lower levels of:

The language used by healthcare professionals can have a profound impact on how patients experience their condition and feel about living with it day-to-day; use collaborative language, aim to be more empathic, empowering, respectful, and culturally competent.

In the SURPASS-4 trial of patients with T2DM and at high cardiovascular risk, the lowest risk of a 4-point major adverse cardiovascular events composite endpoint was observed in participants treated with:

Predictors of ≥15% weight reduction and associated changes in cardiometabolic risk factors with tirzepatide treatment include: